Theravance Biopharma (TBPH) Net Income towards Common Stockholders (2013 - 2026)

Theravance Biopharma (TBPH) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$5.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 63.4% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at $82.1 million (up 240.79% YoY), while the FY2025 annual figure was $70.1 million, up 224.23% from the prior year.
• Net Income towards Common Stockholders fell to -$5.0 million in Q1 2026 per TBPH's latest filing, from $28.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $927.1 million in Q3 2022 and bottomed at -$21.7 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged $54.4 million across 5 years, with a median of -$5.3 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 4400.0% — and 2023, when it sank 239.1%.
• Theravance Biopharma's Net Income towards Common Stockholders stood at $3.9 million in 2022, then plunged by 236.18% to -$5.3 million in 2023, then tumbled by 192.8% to -$15.5 million in 2024, then jumped by 284.5% to $28.6 million in 2025, then sank by 117.35% to -$5.0 million in 2026.
• Business Quant data shows TBPH's Net Income towards Common Stockholders at -$5.0 million in Q1 2026, $28.6 million in Q4 2025, and $3.6 million in Q3 2025.